London
· Delayed Price · Currency is GBP · Price in GBX MaxCyte Company Description
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.
MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 1998 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Maher Masoud |
Contact Details
Address: 9713 Key West Avenue Rockville, Delaware 20850 United States | |
| Phone | 301 944 1700 |
| Website | maxcyte.com |
Stock Details
| Ticker Symbol | MXCT |
| Exchange | London Stock Exchange AIM |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US57777K1060 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maher Masoud | Chief Executive Officer |
| Douglas Swirsky | Chief Financial Officer |
| Jay Gelfman | Chief Operating Officer |